Literature DB >> 10780288

Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice.

C M Baratti1, M M Boccia.   

Abstract

Sildenafil (1, 3, 10, and 30mg/kg, intraperitoneally (i.p.)), a cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) inhibitor, facilitated retention performance of a one-trial step-through inhibitor avoidance task, when administered to male Swiss mice immediately after training, as indicated by performance on a retention test 48 h later. The dose-response curve was an inverted U in this dose range, although only the dose of 3 mg/kg of sildenafil produced significant effects. Sildenafil did not affect response latencies in mice not given the footshock on the training trial, indicating that the actions of sildenafil on retention were not due to non-specific proactive effects on retention performance. The effects of sildenafil (3 mg/kg, i.p.) were time-dependent, and the administration of sildenafil (3 mg/kg, i.p.) 30 min prior to the retention test did not affect retention in mice given post-training injections of vehicle or sildenafil (3 mg/kg, i.p.). However, the administration of sildenafil (3mg/kg, i.p.) 30 min before training also enhanced retention performace. Further, when mice were trained and received immediate post-training sildenafil (3 mg/kg) and were tested for retention either 1 week or 1 month later, at each retention interval the performance was comparable to that found with a 48-h retention interval. Finally, an enhancement of retention was also observed in female Swiss mice that received sildenafil (3 mg/kg, i.p.) immediately, but not 180min, after training. These findings could indicate that the actions of sildenafil on retention are not sex-dependent. The results suggest that sildenafil influences retention by modulating time-dependent mechanisms involved in memory storage and that the effects are long lasting. A possible participation of the nitric oxide (NO)-guanylyl cyclase-cGMP system also is suggested.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10780288     DOI: 10.1097/00008877-199912000-00004

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  20 in total

1.  Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition.

Authors:  Bryan D Devan; Jonna L Bowker; Kara B Duffy; Ila S Bharati; Mariana Jimenez; Demetrio Sierra-Mercado; Christopher M Nelson; Edward L Spangler; Donald K Ingram
Journal:  Psychopharmacology (Berl)       Date:  2005-11-18       Impact factor: 4.530

2.  Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimer's Disease.

Authors:  Min Sheng; Hanzhang Lu; Peiying Liu; Yang Li; Harshan Ravi; Shin-Lei Peng; Ramon Diaz-Arrastia; Michael D Devous; Kyle B Womack
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

3.  The effect of L-NAME and L-arginine on impairment of memory formation and state-dependent learning induced by morphine in mice.

Authors:  Simin Khavandgar; Houman Homayoun; Mohammad Reza Zarrindast
Journal:  Psychopharmacology (Berl)       Date:  2003-03-28       Impact factor: 4.530

4.  Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: acquisition versus consolidation.

Authors:  Jos Prickaerts; Ayhan Sik; Franz Josef van der Staay; Jan de Vente; Arjan Blokland
Journal:  Psychopharmacology (Berl)       Date:  2004-07-24       Impact factor: 4.530

5.  Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.

Authors:  Jole Fiorito; Faisal Saeed; Hong Zhang; Agnieszka Staniszewski; Yan Feng; Yitshak I Francis; Sudha Rao; Devarshi M Thakkar; Shi-Xian Deng; Donald W Landry; Ottavio Arancio
Journal:  Eur J Med Chem       Date:  2012-12-14       Impact factor: 6.514

Review 6.  Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.

Authors:  Elisa Zuccarello; Erica Acquarone; Elisa Calcagno; Elentina K Argyrousi; Shi-Xian Deng; Donald W Landry; Ottavio Arancio; Jole Fiorito
Journal:  Biochem Pharmacol       Date:  2020-01-21       Impact factor: 5.858

7.  The proconvulsant effect of sildenafil in mice: role of nitric oxide-cGMP pathway.

Authors:  Kiarash Riazi; Maryam Roshanpour; Neda Rafiei-Tabatabaei; Houman Homayoun; Farzad Ebrahimi; Ahmad Reza Dehpour
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

Review 8.  Phosphodiesterases as therapeutic targets for Alzheimer's disease.

Authors:  Ana García-Osta; Mar Cuadrado-Tejedor; Carolina García-Barroso; Julen Oyarzábal; Rafael Franco
Journal:  ACS Chem Neurosci       Date:  2012-10-01       Impact factor: 4.418

Review 9.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

10.  A placebo-controlled study of sildenafil effects on cognition in schizophrenia.

Authors:  Donald C Goff; Corinne Cather; Oliver Freudenreich; David C Henderson; A Eden Evins; Melissa A Culhane; Jared P Walsh
Journal:  Psychopharmacology (Berl)       Date:  2008-08-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.